Compare EPOW & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPOW | EVAX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | China | Denmark |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 25.8M |
| IPO Year | 2019 | 2020 |
| Metric | EPOW | EVAX |
|---|---|---|
| Price | $0.55 | $3.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 119.4K | 24.3K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $2.45 |
| 52 Week High | $1.86 | $12.15 |
| Indicator | EPOW | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 40.93 |
| Support Level | N/A | $2.97 |
| Resistance Level | $0.73 | $3.62 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 2.60 | 24.88 |
E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. It operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, the Group also operates a knowledge-sharing platform business. Its reportable operating segments are: Graphite anode business, which generates the maximum revenue, and Knowledge sharing and enterprise business. Substantially all of the Group's revenue is derived in the People's Republic of China (the PRC).
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.